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Prostate cancer (PC) progression from androgen-dependent (AD) to castration-resistant (CR) disease is a process caused by
modifications of different signal transduction pathways within tumor microenvironment. Reducing cell proliferation, estrogen
receptor beta (ERbeta) is emerging as a potential target in PC chemoprevention. Among the known selective ERbeta ligands,
3beta-Adiol, the endogenous ligand in the prostate, has been proved to counteract PC progression. This study compares the effects
of chronic exposure (1–12 weeks) to different ERbeta selective ligands (DPN, 8beta-VE2, 3beta-Adiol) on proliferation of human
androgen-responsive CWR22Rv1 cells, representing an intermediate phenotype between the AD- and CR-PC. 3beta-Adiol (10 nM)
is the sole ligand decreasing cell proliferation and increasing p21 levels. In vitro transcriptional activity assays were performed to
elucidate different behavior between 3beta-Adiol and the other ligands; in these experiments the endogenous and the main ERbeta
subtype activation were considered. It is concluded that ERbeta activation has positive effects also in androgen-responsive PC.The
underlying mechanisms are still to be clarified and may include the interplay among different ERbeta subtypes and the specific
PC microenvironment. ERbeta agonists might be useful in counteracting PC progression, although the final outcome may depend
upon the molecular pattern specific to each PC lesion.
This paper is dedicated to the memory of our colleague and dear friend Donatella Dondi.
1. Introduction
Prostate cancer (PC) represents one of the main leading
causes of death in men worldwide [1]. This is mainly due
to a high rate recurrence and progression of the disease to
a castration-resistant and disseminated stage (CR-PC), in
which therapeutic options are few and often only palliative
[1]. Thus, the discovery of drugs able to positively manage
CR-PC and/or to delay its appearance still represents an
important clinical challenge.
Estrogens, alone or along with androgens, are impor-
tant players of prostate carcinogenesis and progression.
Indeed, chronically high estrogenic levels are associated with
increased risk to develop PC. However, anticancer activity
has been observed in many instances by using synthetic
or herbal-derived estrogens [2–5]. These conflicting obser-
vations are possibly due to the presence of two classes of
estrogen receptors (ERalpha andERbeta) [6, 7], which display
differences in localization, expression levels, and functional
roles in prostate biology and carcinogenesis. ERbeta, which
is largely localized in the epithelial compartment, is linked
to antiproliferative and differentiating effects [7–12]. In vitro
data have shown how ERbeta-driven inhibitory activity on
PC biology might be mediated by induction of apoptosis
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[12], by enhanced synthesis of cell cycle inhibitor proteins
[4, 13], or by a negative regulation of cell adhesion molecules
[14]. Furthermore, the loss of ERbeta is associated with the
progression from normal prostate epithelium to PC [15]. All
these findings point to a major role of ERbeta to protect
prostate cells from uncontrolled proliferation and malignant
transformation. Thus, ERbeta activation by specific agonists
may be a feasible option treatment for PC chemoprevention
and CR-PCmanagement. However, the mechanism of action
of ERbeta is rather complex and still unclear due to the
discovery of at least five ERbeta different isoforms resulting
from alternative splicing of the same gene. Among them,
ERbeta1, 2, and 5 are the most studied isoforms in human
PC. ERbeta1, which is the one primarily lost during PC
progression, is defined as the wild-type isoform and it is
related to the antiproliferative and the proapoptotic activity
[12, 16].On the contrary, ERbeta2 andERbeta5 bind estrogens
with different affinity (none and low affinity, resp., [17]) and
are associated to increased cell proliferation and enhanced
cell migration, as well as to a PC poor prognosis [18, 19]. It
is suggested that these isoforms, which are often coexpressed
with ERbeta1 in many tissues, including the prostate [16,
17, 20, 21], bind as homo- or heterodimers to canonical
ERE sequences and act as variable parameters with enhancer
or dominant negative functions [17, 18, 20, 22]. Moreover,
coexpression of ERbeta1 with ERbeta2 or ERbeta5 inHEK293
cells significantly enhances ERE-mediated transactivation
when activated by estradiol or phytoestrogens [17]. To our
knowledge, the ability of these complexes to activate tran-
scription upon binding with ERbeta selective agonists has
never been evaluated.
Thanks to the significant differences in the ligand binding
domain between ERalpha and ERbeta, a series of ERbeta
selective agonists have been developed in these last years
[5, 23, 24], and most of them have been also tested for
their biological activity in different experimentalmodels [25–
28]. The various ERbeta selective agonists have the same
transcriptional activity on a battery of genes; however, it is
demonstrated that theymay also display gene-specific activa-
tion/repression resulting in distinct biological outcomes and
possibly clinical effects [29]. The fact that different ERbeta-
selective agonists might elicit different biological results
points to the need of a careful evaluation of diverse structural
classes of compounds in various disease models to identify
the optimal ERbeta agonist in each condition.
Owing to the largely planar configuration of the phy-
toestrogens (the first ERbeta selective ligands discovered),
nonsteroidal compounds retaining a similar topology have
been synthesized; among these, diarylpropionitrile (DPN)
is considered the prototype molecule of the group [5, 23].
However, compounds with nonplanar rigid configuration
have shown a more robust and greater selectivity for ERbeta
than the planar ones [5]. The prototype of this latter
group is 8vinylestrane-1,3,5(10)-triene-3,17beta-diol (8beta-
VE2) [5]. High affinity for ERbeta is also displayed by 5alpha-
androstane-3beta,17beta-diol (3beta-Adiol), an endogenous
metabolite of DHT which classically does not bind to the
wild-type AR [30]. As the intraprostatic levels of 3beta-Adiol
in vivo are about 100-folds higher than those of estradiol, this
steroid is considered the natural ligand of ERbeta in the gland
[11].
Among the different available in vitro PC models, the
CWR22RV1 (Rv1) cells, which are derived from a primary
androgen-dependent human PC tumor (CWR22) ortho-
topically transplanted in castrated nude mice, represent an
intermediate phenotype between the AR-dependent and
castration-resistant tumor. Rv1 cells are androgen ablation-
resistant, but still androgen-responsive [31, 32]. They express
ARs (both wild-type andmutated forms [33]), but conflicting
results are reported on the expression levels of ERalpha and
ERbeta [12, 34]. Due to the 35/40-h doubling time, they
represent a suitable cell-basedmodel, resembling the “in vivo”
condition, to study the effect of a long-lasting treatment on
cell proliferation [31].
The aimof the studywas to evaluate in Rv1 cell line; (a) the
expression of the different isoforms of androgen and estrogen
receptors; (b) the effects driven by a chronic exposure toDPN,
8beta-VE2, and 3beta-Adiol on cell proliferation rate, on the
expression of AR and ER gene levels and on the expression
of some proteins involved in cell cycle arrest (PTEN, p21
and cyclin E). A series of in vitro transcriptional activity
assessments were then performed to elucidate the different
behavior between 3beta-Adiol and the other ERbeta selective
ligands in Rv1 cell.
2. Material and Methods
2.1.Chemicals and Plasmids. 2,3-bis(4-hydroxyphenyl)-pro-
pionitrile (DPN, Tocris Cookson, Ellisville, MO, USA),
8vinylestrane-1,3,5(10)-triene-3,17beta-diol (8beta-VE2,
kindly provided by Dr. K. Prelle, Bayer Schering Pharma
AG), and 5alpha-androstane-3beta,17beta-diol (3beta-Adiol,
Sigma-Aldrich, Milano, Italy) were used as ERbeta selective
agonists. ICI 182,780 (Tocris Cookson, Ellisville, MO, USA)
was used as estrogen receptor antagonist. All compounds
were dissolved in ethanol.
pCMV5-ERbeta1, pCMV5-ERbeta2, pCMV5-ERbeta5,
and pCMV5-EMPTY were kindly provided by Dr. P. G. V.
Martini, Shire HGT, Boston, MA; pGL3-2ERE-pS2-luc was
kindly provided by Dr. M.Marino, Rome, and pgL 4.0 hRLuc
was from Promega (Milano, Italy).
2.2. Cell Cultures and Treatments. CWR22Rv1 (Rv1) cells
were originally obtained from DSMZ (Frankfurt, Germany);
HEK293 cell line was originally obtained by American Type
Culture Collection (Rockville,MD) and currently used in our
laboratory.
All cell culture reagents were purchased from Biochrom
(Biochrom KG, Berlin, Germany). Rv1 cells were routinely
grown at 37∘C in a humidified atmosphere (5% CO
2
—95%
air) in 100mm Petri dishes in phenol red free RPMI 1640
supplemented with 5% of heat inactivated fetal calf serum
(FCS, GIBCO), glutamine (2mM), penicillin (100 IU/mL),
and streptomycin (100microg/mL). Medium was changed
biweekly. HEK293 were routinely maintained in the same
culture conditions in 10% FCS phenol red free RPMI
1640.
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Table 1
Target gene Forward primer Reverse primer
ERbeta1 GTCAGGCATGCGAGTAACAA GGGAGCCCTCTTTGCTTTTA
ERbeta2 TCTCCTCCCAGCAGCAATCC GGTCACTGCTCCATCGTTGC
ERbeta5 GATGCTTTGGTTTGGGTGAT GGAGGAGTGGGTGTCGCTGT
Beta-actin CCACCATGTACCCTGGC CGGACTCGTCATACTCCTGC
Table 2
Target protein Primary antibody Secondary antibody
ERbeta (all)
Ab288
(Abcam, Cambridge, UK);
1 : 500 dilution
WesternDot 625 detection kits
(Life Technologies Italia, Monza, Italy);
1 : 2000 dilution
AR
Sc816
(Santa Cruz Biotechnology, Santa Cruz, CA, USA);
1 : 400 dilution
HRP-conjugated anti-rabbit
(Santa Cruz Biotechnology, Santa Cruz, CA, USA);
1 : 2000 dilution
PTEN
ab32199
(Abcam, Cambridge, UK);
1 : 1000 dilution
HRP-conjugated anti-rabbit
(Santa Cruz Biotechnology, Santa Cruz, CA, USA);
1 : 8000 dilution
p21
05-345
(Millipore, Billerica, MA, USA);
1 : 1000 dilution
HRP-conjugated anti-mouse
(Santa Cruz Biotechnology, Santa Cruz, CA, USA);
1 : 5000 dilution
Tubulin
T9026
(Sigma-Aldrich, Monza, Italy);
1 : 2000 dilution
HRP-conjugated anti-mouse
(Santa Cruz Biotechnology, Santa Cruz, CA, USA);
1 : 8000 dilution
Beta-actin
Sc1616
(Santa Cruz Biotechnology, Santa Cruz, CA, USA);
1 : 4000 dilution
HRP-conjugated anti-goat
(Santa Cruz Biotechnology, Santa Cruz, CA, USA);
1 : 4000 dilution
2.3. Experimental Schedule in Long-Term Experiments. Rv1
cells were seeded in 100mm Petri dishes in phenol-red free
RPMI 1640 supplemented with 5% charcoal stripped-FCS
(FCS-CH) (2 independent samples/treatments/times) and
chronically treated every 2 days with ethanol (control cells),
DPN, 8beta-VE2, or 3beta-Adiol (all 10 nM) up to 12 weeks,
on a weekly propagation schedule. At the beginning of the
long-term exposure (T1) and after 5, 8, and 12 weeks (T5–T12)
of chronic treatment, part of the cells from each group was
harvested and utilized for RNA/protein extraction and for the
growth rate evaluation.The schedule of chronic treatments is
outlined in Figure 1.
2.4. Growth Rate Evaluation. Cells from the chronic expo-
sure were seeded in 100mm Petri dishes in 5% FCS-
CH phenol-red free RPMI 1640 (3 independent sam-
ples/treatments/times) and the corresponding treatment
went on every 2 days for 10 days. After 3, 5, 7, and 10 days, cells
from some of the Petri dishes were harvested and counted by
Tripan blue exclusion in a Burker chamber (see Figure 1).
2.5. Real-Time PCR. Total RNA from control and treated cells
was extracted by the phenol-chloroform method according
to standard protocols [35] and used for real-time PCR
(qPCR). A mean of 2 independent RNA samples was used
for each determination. Reverse transcription was performed
on 1 𝜇g of total RNA from each sample according to the
manufacturer’s protocol (iScript cDNA synthesis kit, BioRad,
Segrate, Italy) using random primers. qPCR was done in
singleplex in CFX96TouchReal-Time PCRDetection System
(BioRad, Segrate, Italy) using two different experimental
protocols: ERalpha, ERbeta and AR genes were amplified
using the SsoFast Probes supermix (BioRad, Segrate, Italy)
and specific assays on demand (AoD, Life Technologies,
Monza, Italy); ERbeta isoforms were amplified using the
SsoAdvanced SYBR Green SuperMix (BioRad, Segrate, Italy)
and the specific sets of primers listed in Table 1, designed
using the Primer 3 software and purchased by Sigma Aldrich,
Milano, Italy.
Each sample was analysed in triplicate. Relative mRNA
levels were calculated using the comparative CT method
(2
−ΔΔCt
).
2.6. Western Blot Analysis. Constitutive proteins from con-
trol and treated cells were prepared by lysing in RIPA
buffer with proteases inhibitors. Total proteins extracts (30
microgr/sample), determined with BCA assay (Pierce, Rock-
ford, IL, USA), were resolved on SDS-PAGE followed by
electrotransfer onto nitrocellulose membrane. The fluores-
cent qDot system (Life Technologies Italia, Monza, Italy) was
used for ERbeta detection; the enhanced chemiluminescence
(ECL) detection kit (GE Healthcare, Milano, Italy) was used
for AR, PTEN, and p21 detection. Specific primary and
secondary antibodies are listed in Table 2.
2.7. Transient Transfections andTranscriptional Activity Assay.
Rv1 orHEK-293 cells, plated in 96-wells plate andmaintained
in RPMI 1640 without phenol-red and FCS, have been
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RNA and PROTEIN extraction for the evaluation of:
T12T8T5
Weeks of 
treatment
Cell seeding for exponential growth evaluation  
(treatments every 2 days)
T1
✓ ERs (qRT-PCR)
✓ AR isoforms (qRT-PCR, western blot analysis)
✓ PTEN, p21 and cyclin E (western blot analysis)
Figure 1: Experimental schedule of chronic treatment.
transfected by using Lipofectamine 2000 (Life Technologies
Italia,Monza, Italy). Transfectionwas performed using a total
of 0.2 microgr of plasmid DNAs/well, according to manu-
facturer’s protocol. After 6 hours, the transfection medium
was replaced with RPMI 1640 without phenol-red with 5%
(Rv1) or 10% (HEK 293) FCS-CH containing the appropriate
treatment. Transcriptional activity was evaluated 22 hours
later by the luciferase assay (DUAL-GLO Luciferase Assay
System kit, Promega, Milano, Italy), according to the man-
ufacturer’s protocol. The inducible firefly luciferase activity
has been normalized by renilla luciferase. Each sample was
assessed in duplicate.
2.8. Statistical Analysis. The statistical analysis of the row
data was performed by one-way parametric ANOVA and
expressed as mean ± SD; post hoc analyses were performed
by Tukey’s Multiple Comparison Test, using the Graph-Pad
software for Macintosh (Evanston, IL). Only P values < 0.05
were considered statistically significant.
Cell growth rate was analyzed by an exponential curve
fitting computer program (ESPSS) followed by the statistical
analysis of the fitted curve parameters through parametric
ANOVA and by the Student-Newman-Keuls post hoc Test for
multiple comparisons. Only P values < 0.05 were considered
statistically significant.
3. Results
3.1. Steroid Hormone Receptor Pattern in Rv1 Cells. Due to
conflicting data on ERbeta expression in Rv1 cells, first of
all we have assessed the presence of the endogenous ERs,
along with that of ARs in our experimental model (Figure 2).
Panel (a) shows the expression pattern of ERalpha, ERbeta
and of the 110 kDa form of AR, evaluated by qPCR and
expressed as % versus the 110 + 75 AR transcripts (AR total)
after normalization for the housekeeping gene HPRT. It is
apparent from the panel that this cell line expresses both
ERalpha and ERbeta. Even though the levels of ERbeta are
higher than those of ERalpha, taken as awhole, the expression
of the two ER is very low in comparison to that of ARs;
the 110 kDa AR represents roughly 20% of the totality of AR
transcripts. In this qPCR experiment AR75 was not evaluated
separately due to the impossibility to design a set of specific
primers.
To confirm the presence of ERbeta also at protein level,
Western blot analysis was performed on two independent
RV1 samples using an antibody that maps to the N-terminus
(common to all the ERbeta subtypes, see below). Figure 2(b)
shows the presence of at least three immunoreactive bands
with a MW within the 50–60 kDa range, which might
correspond to the three main ERbeta subtypes present in CP
cells [17]. AR75 and AR110 expression levels were evaluated
separately byWestern blot analysis. A representativeWestern
blot carried out using a polyclonal antibody directed against
the amino-terminus of the protein, which recognizes all the
different AR forms, is shown in panel (c). It is evident that
Rv1 cells contain both the AR form of 110 kDa (considered
the wild type) and that of 75–80 kDa, corresponding to some
forms truncated at the carbossi-terminal; panel (d) reports
the mean ± SD of the densitometric analysis of a series of
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Figure 2: Relative expression of ERs and ARs by qPCR (a); Western blot analysis of ERbeta (b) and ARs (c); densitometric analysis of ARs
(d).
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Figure 3: Dose-response effect of ERbeta selective agonists on
short-term (9 days) proliferation of Rv1 cells. Data are mean ± SD
and are expressed as percent of the corresponding controls. ∗𝑃 <
0.05 versus 3beta-Adiol 0.1 nM.
samples after normalizationwith actin. As it appears from the
figure, and in line with the qPCR results, the total amount
of the truncated forms is about threefold higher than that of
AR110, which represent the 20% of the total AR levels.
3.2. Determination of the Optimal Dose for the Chronic
Studies. Previous preliminary experiments performed in our
laboratory using other AR-PC cell lines showed that both
DPN and 8beta-VE2 at the concentration of 10 nM were
able to significantly reduce DU145 cell proliferation after 9
days of exposure (data not shown). Thus, to test the effect
of DPN, 8beta-VE2, and 3beta-Adiol specifically on Rv1 cell
proliferation, the same (10 nM) or a hundred times lower
(0.1 nM) dose of each drug has been administered in a 9-day
treatment schedule (Figure 3).
To compare experiments carried out in different times,
the data in the figure are expressed as percent versus their
own control. As shown, none of the three ligands is effective
at the lower dose. Only 3beta-Adiol is able to significantly
decrease cell proliferation at the dose of 10 nM, being the
same dose of DPN and 8beta-VE2 ineffective in this cell line.
Even though the two latter compounds are ineffective after a
9-day exposure, no higher doses have been tested because of
the possibility of cross-activation of ERalpha [23, 36], or the
achievement of the 100% of the transcriptional activity, as in
the case of 8beta-VE2 [37].
3.3. Rv1 Proliferation Rate during Chronic Exposure. The
proliferation rate of Rv1 chronically exposed to 10 nM DPN,
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Figure 4: Effect of chronic exposure to ERbeta selective ligands on Rv1 cell proliferation: proliferation curves evaluated at T1-5-8-12 with
vehicle (C), 8betaVE2, or 3beta-Adiol (a); with vehicle (C) and DPN (b). Cumulative data of the relative proliferation rate during the chronic
treatments (c): data are mean ± SD and are expressed as percent of the corresponding controls. ∗𝑃 < 0.05 versus the corresponding controls.
8beta-VE2, or 3beta-Adiol has been assessed in two sep-
arate sets of experiments. The corresponding exponential
curves calculated at different weeks during the treatment are
reported in Figures 4(a) and 4(b).
When tests for multiple comparisons have been applied
to the fitted curve parameters, no statistically significant
differences have been detected among the curves for all
compounds at all the time points examined. However, in
the case of cells exposed to 3beta-Adiol a constant decre-
ment is apparent at all the time frames (Figure 4(a)). The
statistical comparison of the last point of each curve only
(10 days of exposure) for each treatment by a restricted
ANOVA analysis shows statistically significant differences in
comparison to control cells at all the time frames (from T1 to
T12) for 3beta-Adiol, while the chronic treatment with 8beta-
VE2 results in a slight but not significant decrease of cell
proliferation (Figure 4(c)). The same figure shows that the
10 nM DPN is completely ineffective, but after 12 weeks of
chronic exposure, when a significant antiproliferative effect
is apparent (Figure 4(c)). In our experimental conditions,
the efficacy of 3beta-Adiol to slow cell proliferation is also
supported by the increase of the doubling time calculated for
the proliferation curves at each time frame in comparison to
the corresponding control cells (from 48–60 h of controls to
65–74 h of 3beta-Adiol treated cells).
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Figure 5: Effects of different chronic treatments with DPN, 8beta-VE2, and 3beta-Adiol on PTEN protein expression in Rv1 cells:
immunoreactive bands (representativeWestern Blot) during chronic treatments (fromT1 to T12) (a); histograms representing the time course
of PTEN protein expression, normalized to the levels of tubulin, grouped by each treatment; values are expressed as mean ± SD (b).
3.4. Influence of the Chronic Exposure on Cell Cycle Regulators
and on AR and ERbeta Levels. To clarify some of the
molecular mechanisms at the basis of the antiproliferative
action of the ERbeta selective agonists, we evaluated by
Western blot analysis the modifications of PTEN (Figure 5)
and of p21 (Figure 6) during the chronic treatment withDPN,
8beta-VE2, and 3beta-Adiol. In both figures, panels (a) show
representative Western blots of PTEN and p21 levels in cells
exposed to the three drugs from T1 to T12, respectively, while
in panels (b) the cumulative results of different experiments
have been pooled together as a function of the treatment and
expressed as fold variation in comparison to the correspond-
ing control samples. As far as PTEN is concerned, the results
show a slight and not significant increase of PTEN levels in
the DPN-treated cells (35% at T12), while neither 8beta-VE2
nor 3beta-Adiol is able to consistently enhance the expression
of this cell cycle regulator (Figure 5(b)). On the contrary, as
clearly appears from the Figure 6(b), only 3beta-Adiol leads
to a progressive significant increase in p21 protein expression
(+41%, 𝑃 < 0.05; +47%, 𝑃 < 0.01, and +78% 𝑃 < 0.01
versus control, from T5 to T12). Treatments with DPN or
8beta-VE2 are completely ineffective. In parallel, only 3beta-
Adiol induces a decrease of cyclin E expression levels (data
not shown).
Neither 3beta-Adiol nor the other ERbeta selective ago-
nists are able to influence the expression levels of AR and
ERbeta, as revealed by qPCR experiments (data not shown).
3.5. Transcriptional Activity of Selective ERbeta Agonists. To
elucidate the different behavior between 3beta-Adiol and the
other ERbeta selective ligands on Rv1 cell growth, first of
all we tested the ability of the compounds to activate tran-
scription through the binding of ERbeta to ERE sequences
(Figure 7). In this set of experiments, a reporter construct
containing 2 estrogen response elements (EREs) coupled to
luciferase has been transiently transfected into Rv1 cells. The
stimulation of the transfected cells with 10 nM 3beta-Adiol
(but not with the 0.1 nM dose) resulted in a huge increase of
luciferase activity (about 35-fold, Figure 7(a), left panel). The
transcriptional activity of 3beta-Adiol is dose-dependently
inhibited by the addition of the pure antiestrogen ICI 182.780
(Figure 7(a), right panel), confirming that Rv1 cells possess an
endogenous transcriptionally active ERbeta and that 3beta-
Adiol, at the doses used in the proliferation studies, medi-
ates the transcription through EREs. Surprisingly, neither
DPN (not shown) nor 8beta-VE2, at the dose of 0.1 and
10 nM, was able to activate the endogenous ERbeta-mediated
transcription in Rv1 cells (Figure 7(a), left panel). On the
contrary, when the full length ERbeta (ERbeta1) was tran-
siently expressed in HEK293 cells together with the 2ERE-
containing gene reporter coupled to luciferase, the exposure
to 8beta-VE2 at the doses of 0.1 and 10 nM results in a dose
dependent increase of the transcriptional activity, while no
response was elicited by the same amounts of 3beta-Adiol
(Figure 7(b))
3.6. Have the Various ERbeta Isoforms a Role in Determin-
ing the Different Activity of 3beta-Adiol and 8beta-VE2? To
answer this question, we first assess by qPCR the expression
pattern of ERbeta subtypes in Rv1 cells in comparison to amix
of RNAs from different AD- and CR-PC cell lines (CWR22,
Rv1, PC3, and DU145 cells). The results obtained, shown in
Figure 8(a), indicate that Rv1 cells possess low but detectable
levels of ERbeta1 and almost three times higher amounts
of ERbeta2; ERbeta5 is the most expressed ERbeta subtype
(about 5 times more than ERbeta1).
Figure 8(b) shows the results of cotransfection exper-
iments in HEK293 cells, in which the ERE-mediated
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Figure 6: Effects of different chronic treatmentswithDPN, 8beta-VE2, and 3beta-Adiol onp21 protein expression inRv1 cells: immunoreactive
bands (representative Western Blot) during chronic treatments (from T1 to T12) (a); histograms showing the time course of p21 protein
expression, normalized to the levels of tubulin, grouped by each treatment; data are expressed as mean ± SD; ∗𝑃 < 0.05 versus corresponding
controls; ∗∗𝑃 < 0.01 versus corresponding controls (b).
transcriptional activity of ERbeta1 alone or along with
ERbeta2 and ERbeta5 was assessed in presence of 3beta-
Adiol or 8beta-VE2. Data are expressed as percent of variation
versus control cells transfected with the same plasmids and
treated with ethanol. First of all it is possible to note that,
in agreement with the previous experiments, 10 nM 8beta-
VE2 stimulates transcription both in presence of ERbeta1
alone and in presence of the two hetero-dimers (2- to 4-
fold of control cells), while 3beta-Adiol is completely inef-
fective. Moreover, when activated by 8beta-VE2, the hetero-
dimer beta1:beta5 induces a significant increase of the ERE-
mediated transcription in comparison to both the homo-
dimer beta1:beta1 and the hetero-dimer beta1:beta2. The
presence of the ERbeta2 subtype in the hetero-dimer causes
a slight but not significant reduction of the ERE-mediated
transcriptional activity in comparison to the homo-dimer
beta1:beta1.
4. Discussion
In the present study we analyzed whether a long-term
activation of ERbeta by selective agonists was able to decrease
the proliferation of Rv1 PC cells and, if so, which are the
underlyingmolecular mechanisms. In particular, we assessed
the effects of DPN [23] and 8beta-VE2 [5] in comparison to
the natural ligand 3beta-Adiol [11]; DPN and 8beta-VE2 are
two known synthetic selective ERbeta agonists, the biological
activity of which have been tested in other mammalian cell
models [25, 26], in comparison to the natural ligand 3beta-
Adiol [11]. Rv1 cells were chosen as a model of primary
androgen-responsive human PC; these cells have also the
advantage to maintain an exponential growth up to 15 days in
vitro and to display a steady doubling time for a long period
[31].
As contrasting results are present in the literature on
ERbeta expression in Rv1 cells [12, 33, 34], we assessed ERbeta
gene and protein expression levels, which were shown to
be low, but detectable. Interestingly, 3beta-Adiol at 10 nM,
a dose that resembles endogenous intraprostatic levels [38],
was found to be the sole ERbeta selective agonist active in
decreasing cell proliferation both after short- (9 days) and
long- (12 weeks) term intervals. Dose (10 nM) and antipro-
liferative effects of 3beta-Adiol appear similar to previously
published data obtained in two commonly used CR-PC cells
(DU145 and PC3 [39]) and in breast cancer cells [40].
This study shows for the first time that 3beta-Adiol
efficacy persists over the timewith a 20–40% reduction of cell
proliferation during 12 weeks of administration. Although
statistically significant at any time, such effect is particularly
evident from 9 days to 5 weeks of administration and less
pronounced over the following time frame (up to 12 weeks).
This may be due to the possible development of some cell
adaptive mechanisms, which, however, are not linked to drug
resistance, as 3beta-Adiol is able to promote a progressive and
significant increase of p21 protein expression.
The involvement of the endogenous ERbeta system in the
mechanismof action of 3beta-Adiol in these cells is supported
by the ability of the compound to activate ERE-mediated
transcription, an effect that is dose-dependently counteracted
by the presence of the pure antiestrogen ICI 182,780. More-
over, long-term administration of 3beta-Adiol and the con-
sequent ERbeta activation are associated with a progressive
increase of p21 expression levels and a slight decrease of the
cyclin E (data not shown), suggesting a potential mechanistic
relationship between these events. These findings appear to
fit well with previous studies, demonstrating that activation
of either the endogenous ERbeta in PC3 [41] and in DU145
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Figure 7: Transcriptional activity of ERbeta agonists in Rv1 (a) and in HEK 293 (b) cells: data are expressed as mean ± SD of the ratio between
the luminescence (RLU) of the experimental over the control reporter; ∗𝑃 < 0.05 versus C and 3beta-Adiol 1 and 10 nM; ∗∗∗𝑃 < 0.001 versus
C and 3beta-Adiol 1 and 10 nM; §§§𝑃 < 0.001 versus C and 8beta-VE2 1 and 10 nM; ∧∧∧𝑃 < 0.001 versus 8beta-VE2 1 nM.
cells [13] or of the stably transfected ERbeta in AD- or CR-
PC cell lines [42, 43] results in the increase of p21 expression
and cell cycle arrest.
During PC progression, PTEN inactivation is an estab-
lished keymodification for the emergence of androgen refrac-
toriness [44]. Moreover, a partial loss of PTEN is extremely
frequent in human primary cancers, particularly in PC,
making the possibility to increase or maintain appropriate
PTEN levels, an important target for chemoprevention. The
ability of ERbeta activation to increase PTEN expression in
cancer cells has been demonstrated by some authors in PC
[45] and in other cancer models [42, 46, 47], but, to our
knowledge, such effect of ERbeta activation over a long time
frame has never been evaluated. To this regard, our results
demonstrated that PTEN expression levels are not influenced
by the activation of the endogenous ERbeta by 3beta-Adiol, as
well as by 8beta-VE2, whereas DPN seems to display a slight
activity from 5 weeks of treatment onward, which however
influences cell proliferation only at the end of the chronic
treatment (T12). These results suggest that in Rv1 cells the
main target of ERbeta in the control of proliferation seems
to be the modulation of cell cycle progression rather than
inhibition of cell survival.
The androgen sensitivity of this cell line [33] is suggested
by our results, demonstrating that the main constitutive
active AR subtype (75 kDa) is much more expressed than the
wild-type AR (110 kDa subtype). One of the criticisms for the
use of 3beta-Adiol in PC cure is its potential retro-conversion
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to DHT [48] and the very recently suggested ability of the
compound to bind also to ARs in some particular conditions
[49]. The results here presented, demonstrating that the
antiproliferative effect of 3beta-Adiol is still present in a
PC cell model expressing functional ARs, are particularly
important, because they suggest a possible use of 3beta-Adiol
(or its analogs) also in the androgen-dependent phase of
PC progression. Interestingly, AR subtype expression in Rv1
cells is not affected by chronic exposure either to 3beta-
Adiol or to the two other ERbeta selective agonists (data not
shown), excluding a possible contribution of AR-mediated
cell proliferation over time.
Chronic DPN administration does not influence cell pro-
liferation with the exception of the last time point evaluated
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(T12). As previously demonstrated in our laboratory, a 9-day
exposure to DPN, at the same dose used in the present exper-
iments, is able to significantly reduce DU145 cell proliferation
[13]. Interestingly, the compound seems to be ineffective
in LAPC-4 and in LNCaP cells, either in the absence or
in the presence of DHT stimulation [50]. Notably, DU145
are CR-PC cells not expressing AR [51], while LAPC-4 and
LNCaP cells are AD and express a 110 kDa AR [51]. Thus,
it seems that, as opposed to 3beta-Adiol, the simultaneous
presence of ERbeta andARmight interfere with DPN activity
on PC cell proliferation. The possible interplay between the
androgenic and estrogenic signaling pathways has apparently
been evaluated only in breast cancer cells [52]. In this model,
AR seems to target classical ERE sequences and it has been
demonstrating an extensive interaction between AR and
ERalpha in the control of target gene transcription, which
results in a blunted proliferative action of ERalpha [52].
The possibility of a cross-talk between AR and ERbeta in
controlling PC functions has never been studied yet but
should be carefully examined in future studies to elucidate
whether a similar mechanism could be active also in tumors
where AR activation is the driving force for proliferation.
8beta-VE2 is as potent as estradiol in binding and activat-
ing ERbeta in prostate preparations [36, 37] and in inducing
apoptosis in human prostatic basal cells [28]. However, the
present study showed that this compound is completely
unable to influence cell proliferation as well as p21 and PTEN
expression in Rv1 cells. In a previously published study using
different experimental conditions and cell models, 8beta-
VE2, at a dose 60 times higher than that used in the present
experiments and after a 12-h exposure, was able to activate the
extrinsic pathway of apoptosis in another PC cell system, the
PC3 cell line [27].
To get a better insight into the interactions of different
ligands with the ERbeta pathway and the consequent biolog-
ical effects (or lack of effect), we assessed the ability of 8beta-
VE2 and 3beta-Adiol to induce ERE-mediated transcription
upon binding either to the endogenous ERbeta in Rv1 cells or
specifically to ERbeta1, transiently transfected into HEK293
cells (a cell line that lacks endogenous ERbeta proteins,
[17]). 3beta-Adiol was able to activate ERE-mediated gene
transcription in Rv1 cells, while 8beta-VE2 was completely
inactive. On the contrary, 8beta-VE2 significantly and dose
dependently stimulates ERE-mediated gene transcription
through ERbeta1 in HEK293 cells, while 3beta-Adiol is
completely ineffective in this experimental model.
One possible explanation of such opposite pattern of
activation might be linked to a specific profile of expression
of ERbeta subtypes in tumor cells and/or the different ability
of the two compounds to bind to these subtypes and to
activate transcription. It is indeed known that the alternative
exon 8 present in the main ERbeta splice variants in humans
(ERbeta2–ERbeta5) confers a conformational change in the
second transactivation domain that alters the ability of the
receptor to bind ligands and recruit cofactors [17]. However,
all ERbeta subtypes can bind to canonical ERE-sequences
on DNA as homo- or hetero-dimers [22]. It is also known
that, during the development and progression of PC, ERbeta1
expression is gradually lost, while that of ERbeta2 and
ERbeta5 increases [19]. Moreover, the relative expression
between ERbeta2 and ERbeta5 differs among the different
transformed prostate cell lines, since ERbeta2 is much higher
than ERbeta5 in PC3 cells, while the opposite pattern is
present in LNCaP cells [22].
The assessment of the relative mRNA expression levels
of the three main ERbeta subtypes present in the human
prostate (ERbeta1, -beta2, and -beta5) in Rv1 cells indicates
that these cells possess low levels of ERbeta1 and higher
levels of ERbeta2 and ERbeta5 (3- and 5-folds versus ERbeta1,
resp.). In theWestern blotting experiments, using an antibody
able to recognize the N-terminus common to all the ERbeta
subtypes (Figure 2(b), multiple bands within the 50–60 kDa
range are shown: the presence of these bands is in agreement
with the results obtained by qPCR and consistent with those
reported by Leung et al. [17].
Differences in the cell response to ERbeta selective ligands
among Rv1 (present results), DU145 [14], and PC3 cells [27]
might be related to a different expression pattern of the
ERbeta subtypes in the three cell lines. To test the possibility
that 3beta-Adiol and 8beta-VE2 show a different transcrip-
tional activity upon binding to ERbeta1, ERbeta2, or ERbeta5,
we overexpressed the three ER subtypes alone or in combina-
tion in HEK293 cells and test the transcriptional activity of
the two compounds by an ERE-coupled reporter gene. 8beta-
VE2 was unable to stimulate transcription in the presence of
ERbeta2 or ERbeta5 alone, confirming the inability of these
ER subtypes to activate ERE-mediated transcription per se.
On the contrary, the compound significantly stimulated gene
transcription when ERbeta wild type was present, giving the
possibility to formERbeta1 homodimers or to heterodimerize
with the other subtypes (ERbeta1:beta2 and ERbeta1:beta5).
Analogous cotransfection experiments have demonstrated
that, in comparison to ERbeta1, the coexpression of ER
subtypes beta1:beta2 and of beta1:beta5 significantly increase
the transcriptional activity of estradiol as well as other
xenoestrogens [17]. In agreement with these findings, in
our experiments, the transcriptional activity of 8beta-VE2
is significantly higher in the presence of the heterodimer
beta1:beta5 in comparison to ERbeta1 alone. However, as
opposed to what presented by these authors, we did not find
significant difference between ERbeta1 alone and the dimer
beta1:beta2. One possibility to explain the different behavior
of 8beta-VE2 might be the propensity of the various ERbeta
agonists to promote ERbeta homo- or heterodimerization. In
line with this hypothesis, also phytoestrogens appear to favor
only ERbeta1 homodimerization [17].
In agreement with the previous results, 3beta-Adiol
appeared to lack any transcriptional activity in ERbeta trans-
fectedHEK293 cells in the presence either of a single or of dif-
ferent receptor subtypes. It should be underlined that in our
experiments we cotransfected equimolar amounts of receptor
subtypes, while, in normal or neoplastic prostate cells, the
relative expression levels are widely variable ([19] and the data
here presented). Thus, the possibility that 3beta-Adiol might
stimulate ERE-mediated transcription only in the presence
of a peculiar ratio among the different ER subtypes cannot
be ruled out. As previously mentioned, the synergistic effect
of ERbeta2 and ERbeta5 on ERbeta1-mediated transcription
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depends on the ligand used. If ERbeta subtypes are expressed
at different levels during the natural history of PC progres-
sion, this peculiar pattern, forming a wide and plastic array
of homo or hetero-dimers, may contribute to the different
pharmacology of the ERbeta selective agonists. The presence
of a functional AR system in Rv1 cells adds a further level of
complexity and might explain the different behavior between
3beta-Adiol and the other synthetic compounds. If part of
the 3beta-Adiol, through its retro-conversion to DHT, binds
to AR [48, 49], the effects observed on cell proliferation and
p21 expression might imply a cross-talk between AR and
ER signaling pathways and the recruitment of a particular
set of coregulators. As previously mentioned, AR can also
target classical ERE sequences and may interact with the ER
systems, as already shown in breast cancer cells [52]. Studies
are in progress in our laboratory to evaluate this hypothesis.
5. Conclusions
The results presented in this paper by using different
ERbeta selective agonists demonstrate that the activation of
the ERbeta pathway has an antiproliferative effect also in
androgen-responsive primary PC tumors and that this activ-
ity is maintained for a long period of time. In addition, from
our results it clearly appears that the mechanism of action
through which ERbeta controls prostate cell proliferation is
still obscure in some aspects because it possibly implies a
complex interplay among ERbeta subtypes (which depends
on their peculiar pattern of expression) and/or an interaction
with the AR system. The high variability of ERbeta subtype
levels in normal, preneoplastic, and cancerous prostatic cells,
including Rv1 ([19] and the data shown here), coupled to
the different behavior of selective ERbeta agonists on PC cell
functions (as appears from our studies), strongly suggests
that a careful assessment of the expression pattern of the
ERbeta subtypes should not be disregarded, when consider-
ing ERbeta-targeted new drugs for PC chemoprevention.
Moreover, if different ERbeta selective agonists might
produce distinct biological and clinical effects, it cannot be
assumed that the lack of effect of one compound in vitro or
in clinical trials may be extended to all the chemical classes
of compounds that bind to ERbeta. In line with this concept,
to prevent and/or slow down PC progression through ERbeta
activation, it should be very important to identify the specific
outcomes of the different ERbeta selective ligands in a PC
specimen of each single patient. This strategy will be helpful
to choose the appropriate drug for the therapy.
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